USFDA grants approval to Zydus Cadila to market Aspirin and Dipyridamole Capsules

USFDA has granted the final approval to Zydus Cadila to market Aspirin and extended-release Dipyridamole Capsules in the strength of 25 mg and 200 mg. The drug is an anti-platelet agent that prevents excessive blood clotting and is used to reduce the risk of stroke in patients who have or had or are at the risk of having a stroke. The drug will be manufactured at the group’s manufacturing facility at Moraiya, Ahmedabad. 
 
The sales of Aspirin and extended-release Dipyridamole Capsules are estimated at USD 198.7 million. The group has more than 140 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
 
Meanwhile, the stock of Cadila Healthcare gained 2.44% at Rs 510.05 per share on BSE at 1055 hours. On the NSE the stock attracted a total traded volume of 6,56,721 shares and a traded value of Rs 3,342.25 lakhs. On a yearly basis the stock has given 31.42% returns and outperformed the BSE Sensex index and BSE Healthcare index.